Dansk Selskab for Almen Medicin logoDansk Selskab for Almen Medicin logo
Klinisk vejledning

Publiseret: 2021

Dyspepsi og gastroøsofageal reflukssygdom hos voksne

Udredning og behandling


  1. www.medstat.dk, 24.02.2020.

  2. Hansen JM, Bytzer P, Schaffalitzky de Muckadell O. Management of dyspeptic patients in primary care: Value of the unaided clinical diagnosis and of dyspepsia subgrouping. Scand J Gastroenterol 1998;33:799-805.

  3. Madsen LG, Bytzer P. The value of alarm features in identifying organic causes of dyspepsia. Can J Gastroenterol. 2000;14:713-20.

  4. Sundhedsstyrelsen: Pakkeforløb for kræft i spiserør, mavesæk og mavemund. København, 2016. ISBN: 978-87-7104-391-4.

  5. Rasmussen S, Haastrup PF, Balasubramaniam K, Christensen RD, Søndergaard J, Jarbøl DE. Predictive values of upper gastrointestinal cancer alarm symptoms in the general population: a nationwide cohort study. BMC Cancer. 2018 Apr 18;18(1):440. doi: 10.1186/s12885-018-4376-8.

  6. Meineche-Schmidt V, Jorgensen T. “Alarm symptoms” in patients with dyspepsia: a three-year pro-spective study from general practice. Scand J Gastroenterol. 2002;37:999-1007.

  7. Gillen D, McColl KE. Does concern about missing malignancy justify endoscopy in uncomplicated dyspepsia in patients aged less than 55? Am J Gastroenterol. 1999;94:75-9.

  8. Phull PS, Salmon CA, Park KG, Rapson T, Thompson AM, Gilbert FJ. Age threshold for endoscopy and risk of missing upper gastrointestinal malignancy data from the Scottish audit of gastric and oesophageal cancer. Aliment Pharmacol Ther. 2006;23:229-33.

  9. Casburn-Jones AC, Murray LS, Gillen D, McColl KE. Endoscopy has minimal impact on mortality from upper gastrointestinal cancer in patients older than 55 years with uncomplicated dyspepsia. Eur J Gastroenterol Hepatol. 2006;18:645-8.

  10. Ford AC, Qume M, Moayyedi P, Arents NL, Lassen AT, Logan RF et al. Helicobacter pylori “test and treat” or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology 2005;128:1838-44.

  11. Eusebi LH, Black CJ, Howden CW, Ford AC. Effectiveness of management strategies for uninvestigated dyspepsia: systematic review and network meta-analysis. BMJ. 2019 Dec 11;367:l6483. doi: 10.1136/bmj.l6483.

  12. Heaney A, Collins JS, Watson RG, McFarland RJ, Bamford KB, Tham TC. A prospective randomised trial of a »test and treat« policy versus endoscopy based management in young Helicobacter pylori positive patients with ulcerlike dyspepsia, referred to a hospital clinic. Gut 1999;45:186-90.

  13. Lassen AT, Pedersen FM, Bytzer P, Schaffalitzky de Muckadell OB. Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial. Lancet 2000;356:455-60.

  14. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev. 2006;CD003840.

  15. Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006;CD002096.

  16. Jarbøl DE, Kragstrup J, Stovring H, Havelund T, Schaffalitzky de Muckadell OB. Proton pump inhibitor or testing for Helicobacter pylori as the first step for patients presenting with dyspepsia? A cluster-randomized trial. Am J Gastroenterol. 2006;101:1200-8.

  17. Jarbøl DE, Bech M, Kragstrup J, Havelund T, Schaffalitzky de Muckadell OB. Economic evaluation of empirical antisecretory therapy versus Helicobacter pylori test for management of dyspepsia: a randomized trial in primary care. Int J Technol Assess Health Care 2006;22:362-71.

  18. Delaney BC, Qume M, Moayyedi P, Logan RF, Ford AC, Elliott C et al. Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). BMJ 2008;336:651-4.

  19. Shin, J.M., Munson, K., Vagin, O. et al. The gastric HK-ATPase: structure, function, and inhibition. Pflugers Arch - Eur J Physiol 457, 609–622 (2009). doi. org/10.1007/s00424-008-0495-4.

  20. Lydeard S, Jones R. Factors affecting the decision to consult with dyspepsia: comparison of consulters and non-consulters. J R Coll Gen Pract. 1989;39:495-8.

  21. Koloski NA, Talley NJ, Huskic SS, Boyce PM. Predictors of conventional and alternative health care seeking for irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther. 2003;17:841-51.

  22. Agreus L, Simrén M. Nya riktlinjer för handläggning av dyspepsi, H pylori och magsår. Läkartidningen 2017;114:ECUW.

  23. Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM. European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017 Jan;66(1):6-30. doi: 10.1136/gutjnl-2016-312288.

  24. Moayyedi P, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG Clinical Guideline: Management of Dyspepsia. Am J Gastroenterol. 2017 Jul;112(7):988-1013. doi: 10.1038/ajg.2017.154.

  25. Bomme M, Hansen JM, Wildner-Christensen M, Hallas J, Schaffalitzky de Muckadell OB. Effects of Community Screening for Helicobacter pylori: 13-Year Follow-Up Evaluation of a Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2017 Nov;15(11):1715-1723.e7. doi: 10.1016/j.cgh.2017.06.006.

  26. Dansk Selskab for Gastroenterologi og Hepatologi: Helicobacter pylori infektion: Diagnostik og behandling. 2018. www.dsgh.dk/index.php/ovre-gi/helicobacter-pylori-infektion-diagnostik-og-behandling

  27. Lanza FL, Chan FK, Quigley EM. Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009 Mar;104(3):728-38. doi: 10.1038/ajg.2009.

  28. Warlé-van Herwaarden MF, Kramers C, Sturkenboom MC, van den Bemt PM, De Smet PA. Dutch HARM-Wrestling Task Force. Targeting outpatient drug safety: recommendations of the Dutch HARM-Wrestling Task Force. Drug Saf. 2012 Mar 1;35(3):245-59.

  29. Dansk selskab for gastroenterologi og hepatologi: Behandling af blødende gastroduodenale ulcera. 2017. www.dsgh.dk/images/Guidelines/pdf/bloedendeulcera.pdf

  30. Petersen J, Møller Hansen J, de Muckadell OBS, Dall M, Hallas J. A model to predict the risk of aspirin/non-steroidal anti-inflammatory drugs-related upper gastrointestinal bleeding for the individual patient. Basic Clin Pharmacol Toxicol. 2019 Nov 25. doi: 10.1111/bcpt.13370.

  31. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, McGowan J. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002;(4):CD002296.

  32. Dansk Cardiologisk Selskab. Behandlingsvejledning. Forebyggelse af hjertesygdom. 2020. nbv.cardio.dk/ihs#361-prognostisk-behandling

  33. Wenfa Wu, Jia Liu, Huiwen Yu, and Zuofeng Jiang. Antiplatelet therapy with or without PPIs for the secondary prevention of cardiovascular diseases in patients at high risk of upper gastrointestinal bleeding: A systematic review and metaanalysis. Exp Ther Med. 2020 Jun; 19(6): 3595–3603.

  34. Francis K L Chan, Jessica Y L Ching, Lawrence C T Hung, Vincent W S Wong, Vincent K S Leung, Nelson N S Kung, Aric J Hui, Justin C Y Wu, Wai K Leung, Vivian W Y Lee, Kenneth K C Lee, Yuk T Lee, James Y W Lau, Ka F To, Henry L Y Chan, S C Sydney Chung, Joseph J Y Sung. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. Engl J Med. 2005 Jan 20;352(3):238-44. doi: 10.1056/NEJMoa042087.

  35. Rikke Sørensen, Morten L Hansen, Steen Z Abildstrom, Anders Hvelplund, Charlotte Andersson, Casper Jørgensen, Jan K Madsen, Peter R Hansen, Lars Køber, Christian Torp-Pedersen, Gunnar H Gislason. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009 Dec 12;374(9706):1967-74. doi: 10.1016/S0140-6736(09)61751-7.

  36. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013 Mar;108(3):308-28. www.dsgh.dk/index.php/ovre-gi/gastrooesofageal-reflukssygdom-diagnostik-behandling

  37. Dansk Selskab for Gastroenterologi og Hepatologi: Gastroøsofageal reflukssygdom: Diagnostik og behandling. 2018. www.dsgh.dk/index.php/ovre-gi/gastrooesofageal-reflukssygdom-diagnostik-behandling

  38. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014 Jun;63(6):871-80. doi: 10.1136/gutjnl-2012-304269.

  39. Rasmussen S, Jensen TH, Henriksen SL, Haastrup PF, Larsen PV, Søndergaard J, Jarbøl DE. Overlap of symptoms of gastroesophageal reflux disease, dyspepsia and irritable bowel syndrome in the general population. Scand J Gastroenterol. 2015 Feb;50(2):162-9. doi: 10.3109/00365521.2014.983157.

  40. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006 Aug;101(8):1900-20.

  41. Gerson LB, Kahrilas PJ, Fass R. Insights into gastroesophageal reflux diseaseassociated dyspeptic symptoms. Clin Gastroenterol Hepatol. 2011 Oct;9(10):824-33. doi: 10.1016/j.cgh.2011.05.015.

  42. Metz DC, Inadomi JM, Howden CW, van Zanten SJ, Bytzer P. On-demand therapy for gastroesophageal reflux disease. Am J Gastroenterol. 2007 Mar;102(3):642-53.

  43. Ford AC, Forman D, Bailey AG, Axon ATR, Moayyedi P. Effect of dyspepsia on survival: a longitudinal 10-year follow-up study. Am J Gastroenterol 2012;107:912-921.

  44. Olafsdottir LB, Gudjonsson H, Jonsdottir HH, Bjornsson E, Thjodleifsson B. Natural history of functional gastrointestinal disorders: comparison of two longitudinal population-based studies. Dig Liver Dis 2012;44:211-217.

  45. Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006 Oct 18;(4): CD001960.

  46. Pinto-Sanchez MI, Yuan Y, Hassan A, Bercik P, Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev. 2017 Nov 21;11:CD011194. doi: 10.1002/14651858.CD011194.pub3.

  47. Ford AC, Luthra P, Tack J, Boeckxstaens GE, Moayyedi P, Talley NJ. Efficacy of psychotropic drugs in functional dyspepsia: systematic review and meta-analysis. Gut. 2017 Mar;66(3):411-420. doi: 10.1136/gutjnl-2015-310721.

  48. Talley NJ, Locke GR, Saito YA et al. Effect of Amitriptyline and Escitalopram on Functional Dyspepsia: A Multicenter, Randomized Controlled Study. Gastroenterology. 2015 Aug;149(2):340-9.e2. doi: 10.1053/j.gastro.2015.04.020.

  49. Lan L, Zeng F, Liu GJ, Ying L, Wu X, Liu M, Liang FR. Acupuncture for functional dyspepsia. Cochrane Database Syst Rev. 2014 Oct 13;(10):CD008487. doi: 10.1002/14651858.CD008487.pub2.

  50. Soo S, Moayyedi P, Deeks J, Delaney B, Lewis M, Forman D. Psychological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD002301.

  51. Orive M, Barrio I, Orive VM et al. A randomized controlled trial of a 10 week group psychotherapeutic treatment added to standard medical treatment in patients with functional dyspepsia. J Psychosom Res. 2015 Jun;78(6):563-8. doi: 10.1016/j.jpsychores.2015.03.003.